SEC Form 4 · accession 0001209191-15-049860
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ran Nussbaum
Director
Period of report
Jun 1, 2015
Accepted (ET)
Jun 3, 2015 · 7:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jun 1, 2015 | S | 69,206 | $55.05 | D | 236,228 | I | See Footnote |
| Common StockF4,F3 | Jun 1, 2015 | S | 3,754 | $56.44 | D | 232,474 | I | See Footnote |
| Common StockF5,F6,F3 | Jun 1, 2015 | S | 7,800 | $57.38 | D | 224,674 | I | See Footnote |
| Common StockF7,F3 | Jun 2, 2015 | S | 200,604 | $55.27 | D | 24,070 | I | See Footnote |
| Common StockF8,F3 | Jun 2, 2015 | S | 24,070 | $56.08 | D | 0 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2015.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55 to $56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F3The shares of common stock are held in the name of Pontifax (Israel) II, L.P., Pontifax (Cayman) II, L.P., and Pontifax (Israel) II - Individual Investors L.P. The reporting person is a director of Pontifax Management 2 G.P. (2007) Ltd., the general partner of Pontifax (Cayman) II, L.P., Pontifax (Israel) II, L.P. and Pontifax (Israel) II - Individual Investors L.P.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.01 to $57.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.02 to $57.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F6Following the sale of shares of common stock in a series of block trades on June 1, 2015, 82,911 shares of common stock were held in the name of Pontifax (Israel) II, L.P., 109,688 shares of common stock were held in the name of Pontifax (Cayman) II, L.P., and 32,075 shares of common stock were held in the name of Pontifax (Israel) II - Individual Investors L.P.
- F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55 to $55.985, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56 to $56.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.